请输入您要查询的百科知识：

　

词条 Peter Bach
释义

  1. Career and education

  2. Other positions

  3. References

  4. External links

{{Multiple issues|{{like resume|date=February 2013}}{{BLP primary sources|article|date=February 2013}}}}{{Infobox medical person
|name = Peter B. Bach
|image = PeterBach.jpg
|alt = A headshot of Bach
|caption =
|birth_date = {{Birth year and age|1964}}
|birth_place =
|death_date =
|death_place =
|profession = Physician, Health Policy Analyst, Writer
|specialty =
|research_field = Healthcare Policy, Epidemiology
|known_for =
|years_active =
|education = Harvard University
University of Minnesota
University of Chicago
|work_institutions = Memorial Sloan-Kettering Cancer Center
|prizes =
|relations =
}}

Peter B. Bach is a physician, epidemiologist, and writer at Memorial Sloan-Kettering Cancer Center where he is Director of the Center for Health Policy and Outcomes.[1] His research focuses on healthcare policy, particularly as it relates to Medicare, racial disparities in cancer care quality, and lung cancer. Along with his scientific writings he is a frequent contributor to The New York Times and other newspapers.

Career and education

Bach chronicled his wife Ruth’s treatment for early breast cancer in a series of articles for the New York Times, and then wrote about her death from the disease in a piece for New York Magazine.[2] Bach discussed the article on Leonard Lopate's show on WNYC.[3]

In 2012, Bach, who is a frequent critic of pharmaceutical pricing in cancer, co-authored an opinion piece in the [https://www.nytimes.com/2012/10/15/opinion/a-hospital-says-no-to-an-11000-a-month-cancer-drug.html?_r=1&mtrref=undefined&gwh=CD8F53FC3BDD4FCD5B65800C288A2921&gwt=pay&assetType=opinion New York Times] outlining Memorial Sloan Kettering’s decision not to offer a new cancer drug, Zaltrap, to its patients due to the drug's price.[4] At the time, the price for Zaltrap was more than twice as high than another cancer drug already being used by the hospital to treat colorectal cancer with similar efficacy. The New York Times piece by Bach was discussed in a 60 Minutes segment highlighting the rising cost of cancer drugs.[5] Bach was seen as influential in the eventual lowering of Zaltrap's price by the manufacturer Sanofi.[6]

In 2015, Bach released DrugAbacus, billed as an interactive tool that users can apply to model prices for cancer drugs based on a number of factors, including clinical efficacy, safety and toxicity, the value placed on a year of life, and the value of innovation. The tool then allows users to compare the generated values with existing drug prices. Additionally, Bach co-authored a paper published in the American Medical Association in which he described possible value-based drug pricing approaches in the United States.[7]{{thirdparty-inline|date=September 2016}}

Bach has also worked on areas related to racial disparities within the provision of cancer care. Along with research collaborators, he has published evidence that black Medicare beneficiaries with lung cancer do not receive as high quality care as white patients.[8][9][10] A paper in 2007 demonstrated that care in Medicare is highly fragmented, with the average beneficiary seeing multiple primary care physicians and specialists.[11] He has worked on developing lung cancer screening guidelines also developed a lung cancer risk prediction model.[12][13][14][15] He has proposed a number of strategies by which Medicare could link payment level to the value of healthcare delivered.[16][17]

His lay press contributions have included op-eds on topics such as medical school tuition funding,[18] setting physician reimbursement based on market forces,[19] and why cancer screening recommendations are often not followed.[20]

Bach earned a bachelor's degree in English and American Literature from Harvard University (1986), a MD from the University of Minnesota (1992) and a Masters of Arts in Public Policy (1997) from the University of Chicago. He obtained his internal medicine training at Johns Hopkins Hospital, and completed a fellowship in Pulmonary and Critical Care Medicine at the University of Chicago and Johns Hopkins Hospital.

Other positions

  • The Centers for Medicare and Medicaid Services (Senior Advisor to the Administrator: 2005-2006)[21]
  • National Cancer Policy Forum of the Institute of Medicine (Member: 2005-current)[22]
  • Working group on HIT for the President’s Council of Advisors on Science and Technology (PCAST) (2009-2011)[23]
  • Institute of Medicine Committee on Geographic Variation in Healthcare Spending (Member: 2010-current)[24]
  • The World Economic Forum's Global Agenda Council on Health Technology (2012-current)[25]

References

1. ^Center for Health Policy and Outcomes Memorial Sloan-Kettering Cancer Center, 2012. (Accessed 11/9/2012)
2. ^{{cite news|last1=Bach|first1=Peter|title=The Day I Started Lying to Ruth|url=http://nymag.com/news/features/cancer-peter-bach-2014-5/|work=New York Magazine|date=May 6, 2014}}
3. ^{{cite news|title=A Cancer Doctor on Losing His Wife to Cancer|url=http://www.wnyc.org/story/cancer-doctor-losing-his-wife-cancer/|work=Leonard Lopate Show on WNYC|date=May 7, 2014}}
4. ^Peter B. Bach, [https://www.nytimes.com/2012/10/15/opinion/a-hospital-says-no-to-an-11000-a-month-cancer-drug.html?adxnnl=1&adxnnlx=1354305797-JyaH/EvyHN7Z2djiZwDpqQ&_r=0 "In Cancer Care, Cost Matters"], The New York Times, 10/14/2012 (accessed 11/30/2012)
5. ^{{cite news|last1=Stahl|first1=Lesley|title=The cost of cancer drugs|url=http://www.cbsnews.com/news/the-cost-of-cancer-drugs/|work=60 Minutes|date=October 5, 2014}}
6. ^Andrew Pollack, [https://www.nytimes.com/2012/11/09/business/sanofi-halves-price-of-drug-after-sloan-kettering-balks-at-paying-it.html "Sanofi Halves Price of Cancer Drug After Sloan-Kettering Rejection"], The New York Times, 11/8/2012 (accessed 11/30/2012)
7. ^{{cite journal|last1=Bach|first1=PB|last2=Pearson|first2=SD|title=Payer and Policy Maker Steps to Support Value-Based Pricing for Drugs.|journal=JAMA|date=15 December 2015|volume=314|issue=23|pages=2503–4|pmid=26619354|doi=10.1001/jama.2015.16843}}
8. ^{{cite journal |name-list-format=vanc|pmid=10519898 |year=1999 |last1=Bach |first1=PB |last2=Cramer |first2=LD |last3=Warren |first3=JL |last4=Begg |first4=CB |title=Racial differences in the treatment of early-stage lung cancer |volume=341 |issue=16 |pages=1198–205 |doi=10.1056/NEJM199910143411606 |journal=The New England Journal of Medicine}}
9. ^{{cite journal |name-list-format=vanc|pmid=15295050 |year=2004 |last1=Bach |first1=PB |last2=Pham |first2=HH |last3=Schrag |first3=D |last4=Tate |first4=RC |last5=Hargraves |first5=JL |title=Primary care physicians who treat blacks and whites |volume=351 |issue=6 |pages=575–84 |doi=10.1056/NEJMsa040609 |journal=The New England Journal of Medicine}}
10. ^{{cite journal |name-list-format=vanc|pmid=11966385 |year=2002 |last1=Bach |first1=PB |last2=Schrag |first2=D |last3=Brawley |first3=OW |last4=Galaznik |first4=A |last5=Yakren |first5=S |last6=Begg |first6=CB |title=Survival of blacks and whites after a cancer diagnosis |volume=287 |issue=16 |pages=2106–13 |journal=JAMA |doi=10.1001/jama.287.16.2106}}
11. ^{{cite journal |name-list-format=vanc|pmid=17360991 |year=2007 |last1=Pham |first1=HH |last2=Schrag |first2=D |last3=O'Malley |first3=AS |last4=Wu |first4=B |last5=Bach |first5=PB |title=Care patterns in Medicare and their implications for pay for performance |volume=356 |issue=11 |pages=1130–9 |doi=10.1056/NEJMsa063979 |journal=The New England Journal of Medicine|citeseerx=10.1.1.622.7686 }}
12. ^{{cite journal |name-list-format=vanc|pmid=12644540 |year=2003 |last1=Bach |first1=PB |last2=Kattan |first2=MW |last3=Thornquist |first3=MD |last4=Kris |first4=MG |last5=Tate |first5=RC |last6=Barnett |first6=MJ |last7=Hsieh |first7=LJ |last8=Begg |first8=CB |title=Variations in lung cancer risk among smokers |volume=95 |issue=6 |pages=470–8 |journal=Journal of the National Cancer Institute |doi=10.1093/jnci/95.6.470}}
13. ^{{cite journal |name-list-format=vanc|pmid=22610500 |year=2012 |last1=Bach |first1=PB |last2=Mirkin |first2=JN |last3=Oliver |first3=TK |last4=Azzoli |first4=CG |last5=Berry |first5=DA |last6=Brawley |first6=OW |last7=Byers |first7=T |last8=Colditz |first8=GA |last9=Gould |first9=MK |last10=Jett |first10=James R. |last11=Sabichi |first11=Anita L. |last12=Smith-Bindman |first12=Rebecca |last13=Wood |first13=Douglas E. |last14=Qaseem |first14=Amir |last15=Detterbeck |first15=Frank C. |title=Benefits and harms of CT screening for lung cancer: A systematic review |volume=307 |issue=22 |pages=2418–29 |doi=10.1001/jama.2012.5521 |journal=JAMA|display-authors=8 |pmc=3709596 }}
14. ^{{cite journal |name-list-format=vanc|pmid=12527567 |year=2003 |last1=Bach |first1=PB |last2=Niewoehner |first2=DE |last3=Black |first3=WC |author4=American College of Chest Physicians |title=Screening for lung cancer: The guidelines |volume=123 |issue=1 Suppl |pages=83S–88S |journal=Chest |doi=10.1378/chest.123.1_suppl.83s}}
15. ^{{cite journal |name-list-format=vanc|pmid=17873161 |year=2007 |last1=Bach |first1=PB |last2=Silvestri |first2=GA |last3=Hanger |first3=M |last4=Jett |first4=JR |author5=American College of Chest Physicians |title=Screening for lung cancer: ACCP evidence-based clinical practice guidelines (2nd edition) |volume=132 |issue=3 Suppl |pages=69S–77S |doi=10.1378/chest.07-1349 |journal=Chest}}
16. ^{{cite journal |name-list-format=vanc|pmid=21383369 |year=2011 |last1=Bach |first1=PB |last2=Mirkin |first2=JN |last3=Luke |first3=JJ |title=Episode-based payment for cancer care: A proposed pilot for Medicare |volume=30 |issue=3 |pages=500–9 |doi=10.1377/hlthaff.2010.0752 |journal=Health Affairs }}
17. ^{{cite journal |name-list-format=vanc|pmid=20921478 |year=2010 |last1=Pearson |first1=SD |last2=Bach |first2=PB |title=How Medicare could use comparative effectiveness research in deciding on new coverage and reimbursement |volume=29 |issue=10 |pages=1796–804 |doi=10.1377/hlthaff.2010.0623 |journal=Health Affairs }}
18. ^Peter B. Bach, [https://www.nytimes.com/2011/05/29/opinion/29bach.html "Why Medical School Should Be Free"], The New York Times, 5/28/2011 (accessed 11/9/2012)
19. ^Peter B. Bach, [https://www.nytimes.com/2009/06/04/opinion/04bach.html "Medicare, Start the Bidding"], The New York Times, 6/3/2009. (accessed 11/9/2012)
20. ^Peter B. Bach, [https://www.nytimes.com/2012/06/05/health/views/essay-urging-doctors-to-do-less-may-fall-on-deaf-ears.html "The Trouble With 'Doctor Knows Best'"], The New York Times, 6/4/2012. (accessed 11/9/2012)
21. ^CMS Seeks Methods to Appropriately Reimburse High-Quality Cancer Care Oncology NEWS International, Vol. 15 No. 2, 2/1/2006. (accessed 11/9/2012)
22. ^National Cancer Policy Forum {{webarchive|url=https://web.archive.org/web/20100308065809/http://www.iom.edu/Activities/Disease/NCPF.aspx |date=2010-03-08 }} Institute of Medicine updated 9/20/2012. (accessed 11/9/2012)
23. ^Report to the President: Realizing the Full Potential of Health Information Technology to Improve Healthcare for Americans PCAST, pg. 7, December, 2010. (accessed 11/9/2012)
24. ^Geographic Variation in Health Care Spending and Promotion of High-Value Care {{webarchive|url=https://web.archive.org/web/20100928111103/http://www.iom.edu/Activities/HealthServices/GeographicVariation.aspx |date=2010-09-28 }} Institute of Medicine updated 8/16/2012. (accessed 11/9/2012)
25. ^Peter Bach World Economic Forum (accessed 11/9/2012)

External links

  • Profile at Memorial Sloan-Kettering Cancer Center Department of Epidemiology and Biostatistics
  • [https://web.archive.org/web/20121026154805/http://www.thirteen.org/openmind/health/do-we-waste-money-on-terminal-patients/2571/ Open Mind TV Show, PBS, 4/12/21. Interview with Richard Heffner, "Do We "Waste" Money on Terminal Patients?"]
  • [https://web.archive.org/web/20121010071549/http://www.thirteen.org/openmind/health/do-we-waste-money-on-terminal-patients-part-ii/2573/ Open Mind TV Show, PBS, 4/12/28. Interview with Richard Heffner, "Do We "Waste" Money on Terminal Patients?" (part 2)]
{{Authority control}}{{DEFAULTSORT:Bach, Peter}}

7 : 1964 births|Living people|American medical researchers|Cancer researchers|Harvard University alumni|University of Chicago Harris School of Public Policy alumni|University of Minnesota Medical School alumni
随便看

　

开放百科全书收录14589846条英语、德语、日语等多语种百科知识，基本涵盖了大多数领域的百科知识，是一部内容自由、开放的电子版国际百科全书。

　

Copyright © 2023 OENC.NET All Rights Reserved
京ICP备2021023879号 更新时间：2024/9/25 18:24:01